In the case at hand, the CEO is an ex-hedge fund manager who is grasping at a big return to pay back some of his furious hedge fund investors. He is also suing a company who fired him for $27 million in severance.
If I understand it correctly, and I may not, the drug in question was patented over sixty years ago and would seem ripe for generic at this price. But the company bypasses pharmacies and strictly controls distribution to hospitals which apparently makes it very difficult to reverse engineer a generic.
It’s not going to hold, ripe for demagoguery given the patient base, and a 5000% increase is going to be very difficult to defend.